Insilico Medicine, Inc. is a Johns Hopkins-based company using artificial intelligence (AI) and deep learning for drug discovery to produce compounds targeted to the diseases of aging.

Insilico will lead by relentlessly innovating, publishing proofs of concept and delivering AI software that deploys the latest technology. A key concept to Insilico’s approach is ruthless internal competition, where different models compete against each other to rapidly prove which is superior and offers greater results.

Insilico Medicine’s “end-to-end” AI platform for drug discovery covers target identification & validation, compound generation and patient selection.

Juvenescence and Insilico have created a joint venture, Generait Pharmaceuticals, that has the first right to five compounds per year from Insilico. Insilico’s capabilities can be leveraged by the Juvenescence partners to speed hit-to-lead discovery.